Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference scheduled for May 20, 2025, at 10 a.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days after the presentation.
Esperion is a commercial-stage biopharmaceutical company that develops FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione al 3° Annuale BioConnect Investor Conference di H.C. Wainwright, previsto per il 20 maggio 2025 alle 10:00 ET. L'evento sarà trasmesso in diretta streaming e sarà accessibile tramite il sito web di Esperion, con la possibilità di rivederlo per circa 90 giorni dopo la presentazione.
Esperion è un'azienda biofarmaceutica in fase commerciale che sviluppa farmaci orali approvati dalla FDA, da assumere una volta al giorno, non statine, per pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro medicinali sono supportati dallo studio CLEAR Cardiovascular Outcomes Trial, che ha coinvolto quasi 14.000 pazienti. L'azienda sta inoltre portando avanti un programma di nuova generazione focalizzato sullo sviluppo di inibitori dell'ATP citrato liasi (ACLYi).
Esperion (NASDAQ: ESPR) ha anunciado su participación en la 3ª Conferencia Anual de Inversores BioConnect de H.C. Wainwright, programada para el 20 de mayo de 2025 a las 10 a.m. ET. El evento será transmitido en línea y estará disponible en el sitio web de Esperion, con una repetición accesible durante aproximadamente 90 días después de la presentación.
Esperion es una empresa biofarmacéutica en etapa comercial que desarrolla medicamentos orales, una vez al día, no estatinas, aprobados por la FDA para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos están respaldados por el ensayo CLEAR Cardiovascular Outcomes, que incluyó a casi 14,000 pacientes. La compañía también está avanzando en su programa de próxima generación enfocado en el desarrollo de inhibidores de la ATP citrato liasa (ACLYi).
에스페리온 (NASDAQ: ESPR)은 2025년 5월 20일 오전 10시(동부시간)에 예정된 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 에스페리온 웹사이트를 통해 웹캐스트로 중계되며, 발표 후 약 90일간 재생이 가능합니다.
에스페리온은 심혈관 질환 및 높은 LDL-C 수치를 가진 환자들을 위한 FDA 승인 경구용 비스타틴계 일일 1회 복용 약물을 개발하는 상업 단계의 생명공학 제약 회사입니다. 이들의 약물은 약 14,000명의 환자를 대상으로 한 CLEAR 심혈관 결과 시험에 의해 뒷받침됩니다. 또한 회사는 ATP 시트르산 분해효소 억제제(ACLYi) 개발에 중점을 둔 차세대 프로그램도 진행 중입니다.
Esperion (NASDAQ : ESPR) a annoncé sa participation à la 3e conférence annuelle BioConnect Investor de H.C. Wainwright, prévue le 20 mai 2025 à 10h00 ET. L'événement sera diffusé en direct sur le site web d'Esperion, avec une rediffusion disponible pendant environ 90 jours après la présentation.
Esperion est une société biopharmaceutique en phase commerciale qui développe des médicaments oraux, non-statine, à prise quotidienne unique, approuvés par la FDA, destinés aux patients souffrant de maladies cardiovasculaires et présentant un taux élevé de LDL-C. Leurs médicaments sont soutenus par l'essai CLEAR Cardiovascular Outcomes, impliquant près de 14 000 patients. L'entreprise fait également progresser son programme de nouvelle génération axé sur le développement d'inhibiteurs de l'ATP citrate lyase (ACLYi).
Esperion (NASDAQ: ESPR) hat seine Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright angekündigt, die für den 20. Mai 2025 um 10 Uhr ET geplant ist. Die Veranstaltung wird per Webcast übertragen und ist über die Website von Esperion zugänglich, mit einer Wiedergabeoption für etwa 90 Tage nach der Präsentation.
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das von der FDA zugelassene orale, einmal täglich einzunehmende, nicht-statinbasierte Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C entwickelt. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes Studie unterstützt, an der fast 14.000 Patienten teilnahmen. Das Unternehmen entwickelt zudem ein nächstes Generationenprogramm, das sich auf die Entwicklung von ATP-Citrat-Lyase-Inhibitoren (ACLYi) konzentriert.
- None.
- None.
ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) presenting at the H.C. Wainwright BioConnect Conference 2025?
What are Esperion's (ESPR) main products and focus?
What is Esperion's (ESPR) next-generation research program?
How long will the webcast replay be available on Esperion's website?
